With more than twenty years of research experience with a focus on oncology, Beth’s findings led to publications in major scientific journals, including Science and Nature, and laid the foundation for the development of a new class of cancer therapeutics, checkpoint inhibitors. In working closely with multiple sectors (academia, industry, non-profit, government, and patient advocacy groups), she identified industry barriers that prevent the transition of promising discoveries for pediatric cancers from academia into a research and development pipeline and ultimately into the clinic. Beth developed innovative business strategies to address these barriers directly and passionately advocates for the creation of public-private partnerships to support rare disease and childhood cancer translational medical research, changes in regulatory policy, and incentives to encourage industry to invest in small patient population markets.